Want to see AU:RCE full AI Analyst Report?
RCE Stock Chart & Stats
AU$0.38
AU$0.02(4.17%)
At close: 4:00 PM EDT
AU$0.38
AU$0.02(4.17%)
Day’s Range― - ―
52-Week RangeAU$0.27 - AU$0.73
Previous CloseN/A
Volume134.82K
Average Volume (3M)123.11K
Market Cap
AU$110.10M
Enterprise ValueAU$124.87M
Total Cash (Recent Filing)AU$2.69M
Total Debt (Recent Filing)AU$10.44M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding305,770,080
10 Day Avg. Volume187,656
30 Day Avg. Volume123,115
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-7.00
Price to Sales (P/S)0.00
P/FCF Ratio-11.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)AU$8.85M
Bulls Say, Bears Say
Bulls Say
Anti-infective PipelineThe pipeline addresses bacterial infections and drug-resistant pathogens, an area of substantial unmet medical need. If clinical development succeeds, these candidates could support differentiated commercial opportunities and provide a longer-term growth platform beyond a single indication or product.
Multiple Clinical FormulationsHaving both topical and intravenous formulations broadens the potential application of the company’s technology across infected wounds and serious bacterial infections. This product breadth may improve strategic flexibility and create more than one route to eventual clinical and commercial value.
Earlier Revenue ExpansionRevenue growth across 2021–2025 indicates the company had previously demonstrated some ability to expand its top line before the latest annual setback. That history provides evidence of commercial progress, although the sharp 2026 decline means the trend is not currently intact.
Bears Say
Revenue CollapseA move to zero revenue with negative gross profit represents a major commercial setback and weakens near-term operating visibility. It also suggests that prior revenue activity has not yet developed into a dependable commercial base capable of supporting ongoing research and development costs.
Persistent UnprofitabilityDeeply negative EBIT, EBITDA and net income show that the business remains far from operating breakeven. Continued losses can consume resources needed for clinical development, reduce financial resilience, and make future progress dependent on additional capital rather than internally generated earnings.
Negative Equity And Funding DependenceNegative equity combined with higher debt indicates limited balance-sheet flexibility and greater dilution or refinancing risk. Persistent operating and free-cash-flow deficits reinforce dependence on external funding, potentially constraining development plans and weakening negotiating power in future capital raises.
Recce Pharmaceuticals Ltd. News
RCE FAQ
What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?
Recce Pharmaceuticals Ltd. lowest share price was AU$0.27 and its highest was AU$0.73 in the past 12 months.
What is Recce Pharmaceuticals Ltd.’s market cap?
Recce Pharmaceuticals Ltd.’s market cap is AU$110.10M.
When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?
Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Mar 01, 2027 which is in 121 days.
How were Recce Pharmaceuticals Ltd.’s earnings last quarter?
Recce Pharmaceuticals Ltd. released its earnings results on Aug 31, 2026. The company reported AU$0.006 earnings per share for the quarter.
Is Recce Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Recce Pharmaceuticals Ltd. pay dividends?
Recce Pharmaceuticals Ltd. does not currently pay dividends.
What is Recce Pharmaceuticals Ltd.’s EPS estimate?
Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recce Pharmaceuticals Ltd. have?
Recce Pharmaceuticals Ltd. has 305,770,080 shares outstanding.
What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?
Recce Pharmaceuticals Ltd. reported an EPS of AU$0.006 in its last earnings report. Following the earnings report the stock price went up 2.18%.
Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:RCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recce Pharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RCE Sentiment 100%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth AU$70.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.19%
12-Months-Change
Fundamentals
Return on Equity
84.67%
Trailing 12-Months
Asset Growth
-31.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.
Technical Analysis
Biotron
―
Starpharma Holdings Limited
―
Immuron Limited
―
Botanix Pharmaceuticals Limited
―
Biome Australia Ltd
―